Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,750 | 179 | 88.3% |
| Education | $758.28 | 16 | 11.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $1,386 | 47 | $0 (2022) |
| ViiV Healthcare Company | $1,337 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $945.71 | 44 | $0 (2023) |
| Gilead Sciences, Inc. | $602.35 | 20 | $0 (2023) |
| Allergan, Inc. | $440.16 | 21 | $0 (2020) |
| Melinta Therapeutics, LLC | $290.49 | 6 | $0 (2024) |
| ABBVIE INC. | $266.00 | 6 | $0 (2023) |
| Shionogi Inc | $261.88 | 3 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $235.15 | 2 | $0 (2023) |
| La Jolla Pharmaceutical Company | $147.21 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $534.65 | 5 | ViiV Healthcare Company ($305.58) |
| 2023 | $1,086 | 10 | ViiV Healthcare Company ($446.51) |
| 2022 | $437.47 | 10 | Astellas Pharma US Inc ($155.74) |
| 2021 | $510.56 | 8 | Shionogi Inc ($116.83) |
| 2020 | $338.34 | 16 | Astellas Pharma US Inc ($131.78) |
| 2019 | $1,890 | 79 | Merck Sharp & Dohme Corporation ($460.96) |
| 2018 | $1,194 | 50 | Astellas Pharma US Inc ($378.77) |
| 2017 | $517.30 | 17 | Astellas Pharma US Inc ($274.49) |
All Payment Transactions
195 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $83.13 | General |
| 10/21/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $117.03 | General |
| Category: HIV | ||||||
| 05/14/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $147.21 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $105.42 | General |
| Category: HIV | ||||||
| 02/07/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $81.86 | General |
| Category: ANTIFUNGALS | ||||||
| 12/13/2023 | NESTLE HEALTHCARE NUTRITION INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $92.33 | General |
| Category: GI | ||||||
| 12/06/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 11/30/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $85.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/14/2023 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $90.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/12/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $124.55 | General |
| 10/12/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $122.08 | General |
| 09/07/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $102.93 | General |
| 08/17/2023 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $123.47 | General |
| Category: HIV | ||||||
| 04/04/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $123.14 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/27/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $96.51 | General |
| 11/03/2022 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $112.01 | General |
| 11/02/2022 | Melinta Therapeutics, LLC | Vabomere (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: ANTIBIOTICS | ||||||
| 05/31/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $94.64 | General |
| Category: HIV | ||||||
| 05/18/2022 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Infectious Diseases | ||||||
| 05/09/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/13/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $66.99 | General |
| 04/13/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.75 | General |
| 03/30/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 03/30/2022 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Infectious Diseases | ||||||
| 03/02/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 197 | 261 | $47,411 | $21,148 |
| 2022 | 8 | 255 | 306 | $56,430 | $25,094 |
| 2021 | 6 | 163 | 223 | $40,948 | $18,333 |
| 2020 | 8 | 173 | 217 | $33,471 | $15,780 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 73 | 78 | $17,784 | $7,944 | 44.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 69 | 122 | $15,352 | $7,500 | 48.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 30 | $6,600 | $2,815 | 42.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $5,040 | $1,903 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 17 | $2,635 | $986.44 | 37.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 53 | 55 | $12,622 | $5,760 | 45.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 36 | $12,164 | $5,537 | 45.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 92 | $11,224 | $5,037 | 44.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 39 | $6,825 | $3,112 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 31 | $6,820 | $2,674 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 23 | $3,565 | $1,498 | 42.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 12 | $2,040 | $933.99 | 45.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 18 | 18 | $1,170 | $540.53 | 46.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 44 | 81 | $9,850 | $4,564 | 46.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 34 | 37 | $8,510 | $3,939 | 46.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 32 | 37 | $8,140 | $3,224 | 39.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $6,096 | $2,826 | 46.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 31 | $5,407 | $2,512 | 46.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 19 | $2,945 | $1,267 | 43.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 46 | 75 | $8,376 | $4,259 | 50.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 34 | 35 | $8,050 | $3,779 | 46.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $4,688 | $2,383 | 50.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 29 | $4,577 | $2,286 | 50.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 22 | 23 | $3,879 | $1,616 | 41.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 17 | $1,987 | $696.71 | 35.1% |
About Dr. Jacob Nichols, MD
Dr. Jacob Nichols, MD is a Internal Medicine healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2014. The National Provider Identifier (NPI) number assigned to this provider is 1831500578.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacob Nichols, MD has received a total of $6,508 in payments from pharmaceutical and medical device companies, with $534.65 received in 2024. These payments were reported across 195 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($5,750).
As a Medicare-enrolled provider, Nichols has provided services to 788 Medicare beneficiaries, totaling 1,007 services with total Medicare billing of $80,355. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hospitalist, Student in an Organized Health Care Education/Training Program
- Location Lubbock, TX
- Active Since 05/15/2014
- Last Updated 12/02/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1831500578
Products in Payments
- AVYCAZ (Drug) $470.04
- ZERBAXA (Drug) $420.92
- CRESEMBA (Drug) $353.78
- DOVATO (Drug) $321.16
- CABENUVA (Biological) $286.70
- ISENTRESS (Drug) $260.38
- Biktarvy (Drug) $218.35
- XACDURO (Drug) $147.21
- Fetroja (Drug) $137.33
- DIFICID (Drug) $133.12
- MYCAMINE (Drug) $126.27
- Cresemba (Drug) $124.38
- REBYOTA (Biological) $123.14
- JULUCA (Drug) $116.17
- Xerava (Drug) $115.31
- XARELTO (Drug) $109.30
- Kimyrsa (Drug) $109.26
- VOWST (Biological) $92.33
- PIFELTRO (Drug) $90.89
- DALVANCE (Drug) $85.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lubbock
Dr. Mohammad Ansari, M.d, M.D
Internal Medicine — Payments: $257,147
Mohammed Bakdash, M.d, M.D
Internal Medicine — Payments: $241,102
Sharma Prabhakar, M.d, M.D
Internal Medicine — Payments: $47,803
Dr. Joseph Wolcott, M.d, M.D
Internal Medicine — Payments: $37,371
Jose Suarez, Md, MD
Internal Medicine — Payments: $36,074
Dr. Michael Mcpherson, Md, MD
Internal Medicine — Payments: $30,601